" class="no-js "lang="en-US"> Luke Devey, BMBCh, Ph.D. - Medtech Alert
Saturday, June 10, 2023

Breaking News

Charles River and INADcure Announce Gene Therapy Manufacturing Collaboration Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas Quell Therapeutics Signs Agreement with AstraZeneca to Develop and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430 FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia Sir Richard Roberts Elected to National Academy of Sciences Rocket Pharmaceuticals Receives FDA Fast Track and Orphan Drug Designations for RP-A601 Gene Therapy for PKP2 Arrhythmogenic Cardiomyopathy (ACM) Azafaros Announces Enrollment of First Patient in Phase 2 RAINBOW Study Evaluating AZ-3102 in GM2 and NP-C Patients Kate Therapeutics Debuts With $51 Million Series A to Develop Next-Generation Genetic Medicines to Treat Muscle and Heart Diseases
Luke Davey | Pharmtech Focus

Luke Devey, BMBCh, Ph.D.

About Luke Devey, BMBCh, Ph.D.

Chief Medical Officer, Quell Therapeutics

Related Story

Appointments

 Quell Therapeutics Appoints Luke Devey

Quell Therapeutics Appoints Luke Devey, BMBCh, Ph.D. as Chief Medical Officer

November 21 2022

Quell Therapeutics Ltd, a world leader in developing engineered T-regulatory (Treg) cell therapies for serious […]